|
Canada-0-LaboratoriesTesting 公司名錄
|
公司新聞:
- Topotecan versus paclitaxel for the treatment of recurrent epithelial . . .
Purpose: Topotecan and paclitaxel were evaluated in a randomized, multicenter study of patients with advanced epithelial ovarian carcinoma who had progressed during or after one platinum-based regimen
- Topotecan versus paclitaxel for the treatment of recurrent epithelial . . .
Topotecan and paclitaxel were evaluated in a randomized, multicenter study of patients with advanced epithelial ovarian carcinoma who had progressed during or after one platinum-based regimen
- Long-term survival in a phase III, randomised study of topotecan versus . . .
Background: We have continued to monitor the survival of patients randomised in a previously reported multicentre phase III study of topotecan versus paclitaxel in patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen
- Long-term survival in a phase III, randomised study of topotecan versus . . .
Overall survival and post-progression survival are potent endpoint in phase III trials of second third-line chemotherapy for advanced or recurrent epithelial ovarian cancer
- Topotecan versus paclitaxel for the treatment of recurrent epithelial . . .
Purpose: Topotecan and paclitaxel were evaluated in a randomized, multicenter study of patients with advanced epithelial ovarian carcinoma who had progressed during or after one platinum-based regimen
- Topotecan for ovarian cancer - PMC
In the seven studies, the median overall survival (OS) of participants treated with topotecan ranged from 39 6 weeks to 63 weeks One study was conducted in women with primary advanced‐stage ovarian cancer; the others were conducted in women with relapsed ovarian cancer
- An Open-Label, Multicenter, Randomized, Phase III Study of Topotecan . . .
Pooled analysis of patients with recurrent ovarian cancer who were treated with topotecan after progression or failure on first- or second-line platinum and paclitaxel
- Long-term survival in a phase III randomised study of topotecan (T) vs . . .
We have continued to monitor the survival of patients randomised in a previously reported multicentre phase III study of topotecan versus paclitaxel in patients with advanced epithelial
- Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian . . .
Data were pooled from eight phase II and phase III clinical studies performed in patients with relapsed stage III IV ovarian cancer or extensive SCLC treated with topotecan at a dose of 1 5 mg m 2 per day on days 1–5 of a 21-day course
- Platinum-Resistant, Recurrent Epithelial Ovarian Cancer (TopoTxt)
To access the safety and tolerability of this novel combination chemotherapy regimen of weekly docetaxel and weekly topotecan in women with recurrent platinum resistant ovarian or primary peritoneal cancer
|
|